Eurican DAP-LR

Not authorised

- Canine distemper virus, strain BA5, Live
- Canine adenovirus 2, strain DK13, Live
- Canine parvovirus, strain CAG2, Live
- Leptospira interrogans, serovar Canicola, strain 16070, Inactivated
- Leptospira interrogans, serovar Icterohaemorrhagiae, strain 16069, Inactivated
- Rabies virus, strain G52, Inactivated

Product identification

Medicine name:
Eurican DAP-LR

Active substance:
Canine distemper virus, strain BA5, Live

Canine adenovirus 2, strain DK13, Live

Canine parvovirus, strain CAG2, Live

Leptospira interrogans, serovar Canicola, strain 16070, Inactivated

Leptospira interrogans, serovar Icterohaemorrhagiae, strain 16069, Inactivated

Rabies virus, strain G52, Inactivated

Target species:
Dog
Dog

Route of administration:

Subcutaneous use

Subcutaneous use

Product details

Active substance and strength:

Canine distemper virus, strain BA5, Live
10000.00 50% tissue culture infectious dose / 1.00 Dose

Canine adenovirus 2, strain DK13, Live
316.23 50% tissue culture infectious dose / 1.00 Dose

Canine parvovirus, strain CAG2, Live
10000.00 50% tissue culture infectious dose / 1.00 Dose

Leptospira interrogans, serovar Canicola, strain 16070, Inactivated
80.00 percentage protection / 1.00 millilitre(s)

Leptospira interrogans, serovar Icterohaemorrhagiae, strain 16069, Inactivated
80.00 percentage protection / 1.00 millilitre(s)

Rabies virus, strain G52, Inactivated
1.00 international unit(s) / 1.00 millilitre(s)

Pharmaceutical form:

Lyophilisate and suspension for suspension for injection

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI07AJ05

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Surrendered

Authorised in:

Germany

Package description:

Available only in German

Available only in German

Available only in German
Available only in German

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)

Marketing authorisation holder:
Boehringer Ingelheim Vetmedica GmbH

Marketing authorisation date:
15/06/2005

Manufacturing sites for batch release:
Boehringer Ingelheim Animal Health France

Responsible authority:
Paul-Ehrlich-Institut

Authorisation number:
396a/87

Date of authorisation status change:
15/10/2021

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.